Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3367MR)

This product GTTS-WQ3367MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Canine B-cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3367MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3265MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ9495MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA J2898A
GTTS-WQ6896MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ7189MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ2896MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG827
GTTS-WQ940MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ10387MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ10043MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA L19-IL-2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW